论文部分内容阅读
目的 探讨原发性肺癌组织中MDM 2、p5 3mRNA表达水平及其与临床预后的关系。方法 采用免疫组织化学DakoEnvisionTM 二步法、逆转录聚合酶链反应 (RT PCR)方法 ,分别检测 5 2例肺癌组织中MDM 2、p5 3mRNA的表达情况。 结果在 5 2例肺癌组织中有 2 3例 (4 4 .2 % )MDM 2蛋白表达阳性 ,其中 3例小细胞肺癌全部阳性 ,在非小细胞肺癌中MDM 2蛋白呈过表达 ,低分化癌明显高于高、中分化肺癌 (P <0 .0 1)。有 2 7例 (5 1.9% )肺癌组织 p5 3mRNA表达阳性 ,其中Ⅰ期肺癌占 82 .3 % (14例 ) ,Ⅱ期肺癌占 71.4% (10例 ) ,明显高于Ⅲ期肺癌的 14 .3 % (3例 )。高中分化肺癌的 p5 3mRNA表达显著高于低分化肺癌 (P <0 .0 5 )。结论 MDM 2蛋白在低分化肺癌中呈过表达 ,p5 3mRNA在早期和高中分化肺癌中呈高表达 ,它们分别是肺癌发生发展过程中不同的 2个基因事件
Objective To investigate the expression of MDM 2, p5 3 mRNA in primary lung cancer and its relationship with clinical prognosis. Methods Immunohistochemical DakoEnvisionTM two-step method and reverse transcription-polymerase chain reaction (RT PCR) method were used to detect the expression of MDM 2 and p5 3 mRNA in 52 lung cancer tissues respectively. RESULTS: Totally 23 (44.2%) MDM 2 proteins were positive in 5 of 52 lung cancer tissues, of which 3 were all small cell lung cancer, MDM 2 protein was overexpressed in non-small cell lung cancer and poorly differentiated carcinoma Was significantly higher than that of high and moderately differentiated lung cancer (P <0.01). There were 27 (5 1.9%) lung cancer tissues with p5 3 mRNA positive expression, of which stage Ⅰ lung cancer accounted for 82.3% (14 cases), stage Ⅱ lung cancer accounted for 71.4% (10 cases), which was significantly higher than stage Ⅲ lung cancer 14. 3% (3 cases). The expression of p5 3 mRNA in high school-differentiated lung cancer was significantly higher than that in poorly-differentiated lung cancer (P <0.05). Conclusions MDM 2 protein is overexpressed in poorly differentiated lung cancer, and p5 3 mRNA is highly expressed in early and high differentiated lung cancer, which are respectively two different genetic events in the development and progression of lung cancer